Journal of Shandong University (Health Sciences) ›› 2022, Vol. 60 ›› Issue (12): 63-68.doi: 10.6040/j.issn.1671-7554.0.2022.0342

Previous Articles     Next Articles

Prognosis of microwave ablation for pulmonary oligometastases after radical resection of non-small cell lung cancer

MA Ruijie1, ZHU Liangming1, ZUO Taiyang1, LI Chunhai2, ZHANG Nan1, SUN Zhigang1   

  1. 1. Department of Thoracic Surgery, Jinan Central Hospital, Shandong University, Jinan 250013, Shandong, China;
    2. Department of Radiology, Qilu Hospital of Shandong University, Jinan 250012, Shandong, China
  • Published:2022-12-01

PDF (PC)

247

Abstract: Objective To evaluate the clinical efficacy of computed tomography(CT)-guided percutaneous microwave ablation(MWA)in the treatment of pulmonary oligometastases after radical resection of non-small cell lung cancer(NSCLC), and to analyze factors affecting survival. Methods The clinical data of 36 patients with pulmonary oligometastases after radical resection of NSCLC during Jan. 2014 and Dec. 2018 were retrospectively analyzed. All patients received CT-guided percutaneous microwave ablation to treat oligometastases. Follow-up and CT examinations were performed on 4-7 days, 1 month and every 3 months after ablation. The overall survival(OS), progression-free survival(PFS)and local progression-free rate were calculated with the Kaplan-Meier method. The differences among groups were compared with Log-rank test, and the independent risk factors were determined with Cox multivariate analysis. Results All patients underwent MWA successfully. Complications occurred in 5 cases(13.9%), including pneumothorax in 3 cases and chest pain in 2 cases. All complications were cured before discharge. The results of Kaplan-Meier and Log-rank test showed that for patients with oligometastatic tumor diameter ≤3 cm, the 3-year PFS and 3-year local progression-free rate were 11.1% and 11.1%, respectively, while for patients with oligometastatic tumor diameter >3 cm, the 3-year PFS and 3-year local progression-free rate were 0.0% and 0.0%, respectively, with statistically significant difference(P<0.001). Cox multivariate analysis showed that oligometastatic tumor diameter >3 cm was an independent risk factor for 3-year PFS(P<0.001)and 3-year local progression-free rate(P<0.001). Besides, no correlation was found between the clinical characteristics and 3-year OS. Conclusion CT-guided percutaneous MWA is safe and effective in the treatment of pulmonary oligometastases after radical resection of NSCLC, and it is practical to delay the local progression of oligometastatic tumors ≤3 cm in diameter.

Key words: Microwave ablation, Thermal ablation, Oligometastase, Oligorecurrence, Non-small cell lung cancer

CLC Number: 

  • R734.2
[1] Rangamuwa K, Leong T, Weeden C, et al. Thermal ablation in non-small cell lung cancer: a review of treatment modalities and the evidence for combination with immune checkpoint inhibitors[J]. Transl Lung Cancer Res, 2021,10(6): 2842-2857.
[2] Vespro V, Bonanno MC, Andrisani MC, et al. CT after lung microwave ablation: normal findings and evolution patterns of treated lesions[J]. Tomography, 2022, 8(2): 617-626.
[3] Chan MV, Huo YR, Cao C, et al. Survival outcomes for surgical resection versus CT-guided percutaneous ablation for stage I non-small cell lung cancer(NSCLC): a systematic review and meta-analysis[J]. Eur Radiol, 2021, 31(7): 5421-5433.
[4] Weichselbaum RR, Hellman S. Oligometastases revisited[J]. Nat Rev Clin Oncol, 2011, 8(6): 378-382.
[5] Niibe Y, Chang JY, Onishi H, et al. Oligometastases/oligo-recurrence of lung cancer[J]. Pulm Med, 2013, 2013: 438236. doi: 10.1155/2013/438236.
[6] Martini N, Melamed MR. Multiple primary lung cancers[J]. J Thorac Cardiovasc Surg, 1975, 70(4): 606-612.
[7] Shen KR, Meyers BF, Larner JM, et al. Special treatment issues in lung cancer: ACCP evidence-based clinical practice guidelines(2nd edition)[J]. Chest, 2007, 132(3 Suppl): 290S-305S.
[8] Ni Y, Peng J, Yang X, et al. Multicentre study of microwave ablation for pulmonary oligorecurrence after radical resection of non-small-cell lung cancer[J]. Br J Cancer, 2021, 125(5): 672-678.
[9] Chetty IJ, Doemer AJ, Dolan JL, et al. MRI-guided Radiotherapy(MRgRT)for treatment of oligometastases: review of clinical applications and challenges[J]. Int J Radiat Oncol Biol Phys, 2022, S0360-3016(22)00745-3.
[10] Han SJ, Cho S, Yum S, et al. Surgical treatment of pulmonary oligorecurrence after curative resection for non-small-cell lung cancer[J]. Interact Cardiovasc Thorac Surg, 2020, 30(1): 18-23.
[11] Wu AJ, Garay E, Foster A, et al. Definitive radiotherapy for kocal recurrence of NSCLC after surgery[J]. Clin Lung Cancer, 2017, 18(3): e161-e168.
[12] Uhlig J, Mehta S, Case MD, et al. Effectiveness of thermal ablation and stereotactic radiotherapy based on stage I lung cancer histology[J]. J Vasc Interv Radiol, 2021, 32(7): 1022-1028.
[13] Habibi M, Berger RD, Calkins H. Radiofrequency ablation: technological trends, challenges, and opportunities[J]. Europace, 2021, 23(4): 511-519.
[14] Li G, Xue M, Chen W, et al. Efficacy and safety of radiofrequency ablation for lung cancers: a systematic review and meta-analysis[J]. Eur J Radiol, 2018, 100: 92-98. doi: 10.1016/j.ejrad.2018.01.009.
[15] Tselikas L, Garzelli L, Mercier O, et al. Radiofrequency ablation versus surgical resection for the treatment of oligometastatic lung disease[J]. Diagn Interv Imaging, 2021, 102(1): 19-26.
[16] 中国临床肿瘤学会 CSCO 肿瘤消融治疗专家委员会, 中国医师协会肿瘤消融治疗技术专家组, 中国抗癌协会肿瘤消融治疗专业委员会, 等. 影像引导下热消融治疗原发性和转移性肺部肿瘤临床实践指南(2021年版)[J]. 中华内科杂志, 2021,60(12): 1088-1105.
[17] Sparchez Z, Mocan T, Radu P, et al. Microwave ablation in the treatment of liver tumors. A better tool or simply more power?[J]. Med Ultrason, 2020, 22(4): 451-460.
[18] Bailey CW, Sydnor MJ. Current state of tumor ablation therapies[J]. Dig Dis Sci, 2019, 64(4): 951-958.
[19] Wei Z, Yang X, Ye X, et al. Microwave ablation plus chemotherapy versus chemotherapy in advanced non-small cell lung cancer: a multicenter, randomized, controlled, phase III clinical trial[J]. Eur Radiol, 2020, 30(5): 2692-2702.
[20] Londero F, Grossi W, Parise O, et al. The Impact of preoperative inflammatory markers on the prognosis of patients undergoing surgical resection of pulmonary oligometastases[J]. J Clin Med, 2020, 9(10): 3378. doi: 10.3390/jcm9103378.
[21] Cheng G, Shi L, Qiang W, et al. The safety and efficacy of microwave ablation for the treatment of CRC pulmonary metastases[J]. Int J Hyperthermia, 2018, 34(4): 486-491.
[22] Meng M, Han X, Li W, et al. CT-guided microwave ablation in patients with lung metastases from breast cancer[J]. Thorac Cancer, 2021, 12(24): 3380-3386.
[23] Izzo F, Granata V, Grassi R, et al. Radiofrequency ablation and microwave ablation in liver tumors: an update[J]. Oncologist, 2019, 24(10): e990-e1005.
[24] Chen B, Li W, Liu Y, et al. The efficacy and complications of computed tomography guided microwave ablation in lung cancer[J]. Ann Palliat Med, 2020, 9(5): 2760-2765.
[25] Ye X, Fan W, Wang H, et al. Expert consensus workshop report: Guidelines for thermal ablation of primary and metastatic lung tumors(2018 edition)[J]. J Cancer Res Ther, 2018, 14(4): 730-744.
[26] Chen B, Li W, Liu Y, et al. The efficacy and complications of computed tomography guided microwave ablation in lung cancer[J]. Ann Palliat Med, 2020, 9(5): 2760-2765.
[27] 丁荣, 牛有权, 黄明, 等. 肺部恶性肿瘤热消融系列并发症防治的文献复习[J]. 中华介入放射学电子杂志, 2021, 9(4): 434-439. DING Rong, NIU Yiuquan, HUANG Ming, et al. Prevention and treatment of a series of complications of thermal ablation in the treatment of lung tumors: a review of the literature[J]. Chinese Journal of Interventional Radiology(Electronic Edition), 2021, 9(4): 434-439.
[28] Xu S, Qi J, Li B, et al. Risk prediction of pneumothorax in lung malignancy patients treated with percutaneous microwave ablation: development of nomogram model[J]. Int J Hyperthermia, 2021, 38(1): 488-497.
[1] HUANG Peiwen, WANG Xudong. A new drug for non-small cell lung cancer: Telisotuzumab Vedotin, an antibody-drug conjugate targeting c-Met protein [J]. Journal of Shandong University (Health Sciences), 2026, 64(3): 124-130.
[2] ZHAO Hanqing, ZHOU Xinrui, LI Zijian, TANG Xing. Application of circulating tumor cells combined with serological detection in non-small cell lung cancer [J]. Journal of Shandong University (Health Sciences), 2025, 63(5): 79-85.
[3] XU Nianxing, WEI Dong, QIAO Junjie, ZHAN Bingyan. Predictive value of CD8+, IL-6, and PaO2 for immunotherapy-triggered radiation recall pneumonitis in unresectable stage ⅢB/C and IV non-small cell lung cancer [J]. Journal of Shandong University (Health Sciences), 2025, 63(2): 29-35.
[4] Thoracoscopic Committee of Shandong Provincial Endoscopic Surgery Quality Control Center. Shandong Provincial expert consensus on control indexes of VATS/RATS perioperative quality for non-small cell lung cancer [J]. Journal of Shandong University (Health Sciences), 2025, 63(12): 1-5.
[5] LIU Zhenkun, LYU Jiling, XU Weiwei, MA Litian, ZHANG Caiqing. Value of tNGS testing and conventional culture for BALF in the diagnosis of NSCLC complicated with IPFD [J]. Journal of Shandong University (Health Sciences), 2025, 63(11): 36-45.
[6] QIN Jing, YANG Fei, CHEN Qian, XIA Handai, LIU Yanguo, WANG Xiuwen. A network meta-analysis of first-line treatment options for patients with advanced driver-gene wild-type and PD-L1 negative non-squamous non-small cell lung cancer [J]. Journal of Shandong University (Health Sciences), 2022, 60(7): 74-82.
[7] CHEN Zhaobo, FANG Min, XUE Haoran, LIU Chunyan. Deubiquitinase USP35 promotes the cells migration and invasion of non-small cell lung cancer [J]. Journal of Shandong University (Health Sciences), 2022, 60(4): 30-37.
[8] Huining LIU,Jun PENG,Yingchun REN,Guang YANG,Wenhao WANG,Jinfeng LIU,Qing TIAN. Comparison of 34 cases of thoracoscopic wedge resection and 21 cases of segmental resection for stage ⅠA1 non-small cell lung cancer in area P [J]. Journal of Shandong University (Health Sciences), 2022, 60(11): 38-43.
[9] DING Zichen, WANG Haohua, ZHOU Liwen, CONG Huiwen, LI Chengsheng, BAO Qihan, YANG Yi, WANG Lianyuan, WANG Suzhen, SHI Fuyan. Study on the individualized efficacy for non-small cell lung cancer patients based on Bayesian Additive Regression Tree model [J]. Journal of Shandong University (Health Sciences), 2022, 60(10): 92-98.
[10] LIU Xiaojing, XIA Xiyan, XIAO Ke, CHEN Wendan, ZHUANG Xuewei. Expression and clinical significance of exosomal long non-coding RNA OGFRP1 in 84 cases of non-small cell lung cancer [J]. Journal of Shandong University (Health Sciences), 2020, 58(11): 71-75.
[11] WEI Ping, DU Lutao, WANG Qing, ZHAN Yao, XIE Yujiao, ZHANG Shujun, DUAN Weili, WANG Chuanxin. Diagnostic value of serum exosomal miR-20b-5p for non-small cell lung cancer [J]. Journal of Shandong University (Health Sciences), 2019, 57(4): 91-96.
[12] WANG Wei, LIU Yongzheng, LI Ling. Effects of Physalin B on proliferation, migration and apoptosis of human non-small cell lung cancer cells [J]. Journal of Shandong University (Health Sciences), 2019, 57(3): 13-18.
[13] WANG Jianli, WANG Xiaojing, SUN Yulian, HU Xiaole, LUAN Xiaorong. Clinical effect of gefitinib combined with chemotherapy on patients with advanced non-small cell lung cancer [J]. Journal of Shandong University (Health Sciences), 2019, 57(11): 20-26.
[14] ZHENG Qingyue, ZHAO Qiuhong, QU Xiangyun, DONG Zhaonan, MA Xueqing, JIA Yunli. Diagnosis value of serum exosome miR-205-5p/miR-152-5p on early non-small cell lung cancer [J]. Journal of Shandong University (Health Sciences), 2019, 57(10): 101-106.
[15] XU Shuyuan, JI Quanjiang, GUO Li. Effects of serum levels of sEGFR, CEA and Cyfra21-1 on the prognosis of non-small cell lung cancer patients [J]. Journal of Shandong University (Health Sciences), 2019, 57(10): 107-111.
Viewed
Full text


Abstract

Cited
  Shared   
  Discussed   
No Suggested Reading articles found!
Copyright 2018 © Editorial office of Journal of Shandong University (Health Sciences)
Supported by Beijing Magtech Co.Ltd